IL10 and neoplasm: Treatment of mice with established B16-OVA tumors or EL4-OVA tumors with IWP-L6 or C59 delayed tumor growth, and this was due to marked increase in tumor-antigen-specific CD4+ and CD8+ effector T cells with reduced number of Tregs, IL-10+ Tr1, and IL-10+ CD8 T cells within the tumors (21).